|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
Prepublished online as a Blood First Edition Paper on May 13, 2002; DOI 10.1182/blood-2002-03-0789.
HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
From the Blood Research Institute, The Blood Center of
Southeastern Wisconsin, and the Department of Pediatrics, The Medical
College of Wisconsin, Milwaukee.
While studying patient plasma containing an unusual pattern of von
Willebrand factor (VWF) multimers, we discovered a previously unreported phenomenon: heavy predominance of dimeric VWF. Genomic analysis revealed a new congenital mutation (Tyr87Ser) that
altered the final stages of VWF biosynthesis. This mutation in the
propeptide (VWFpp) resulted in synthesis of dimeric VWF with an almost
complete loss of N-terminal multimerization. The multimer pattern in
patient plasma appears to result from separate alleles' synthesizing
wild-type or mutant (dimeric) VWF, with homodimers composing the
predominant protomeric species. We have expressed VWF protein
containing the Tyr87Ser mutation and analyzed the intracellular
processing and resulting VWF biological functions. The expressed
dimeric VWF displayed a loss of several specific functions: collagen
binding, factor VIII binding, and ristocetin-induced platelet binding. However, granular storage of dimeric VWF was normal, demonstrating that
the lack of multimerization does not preclude granular storage. Although the tertiary structure of the VWFpp remains unknown, the
mutant amino acid is located in a region that is highly conserved across several species and may play a major role in the multimerization of VWF. Our data suggest that one function of the highly cysteine-rich VWFpp is to align the adjacent subunits of VWF into the correct configuration, serving as an intramolecular chaperone. The integrity of
the VWFpp is essential to maintain the proper spacing and alignment of
the multiple cysteines in the VWFpp and N-terminus of the mature VWF.
(Blood. 2002;100:1699-1706) Von Willebrand factor (VWF) is a large
multimeric glycoprotein with a critical role in maintaining hemostasis.
VWF serves as the carrier protein for the plasma coagulation protein
factor VIII (FVIII) and promotes platelet adhesion and subsequent
aggregation at the sites of vascular damage.1 The
monomeric pro-VWF is composed of 4 repeated domains. The VWF
propeptide (VWFpp) consists of D1-D2 domains, while the mature
VWF protein consists of D'-D3-A1-A2-A3-D4-B-C1-C2 domains.2 VWF undergoes a series of intracellular
modifications, including dimerization, glycosylation, sulfation,
N-terminal multimerization, VWFpp cleavage, and FVIII
binding.3,4 VWF is synthesized exclusively in endothelial
cells and megakaryocytes. In these cells, VWF is packaged in releasable
storage vesicles termed Weibel-Palade bodies in endothelium and
While the extracellular function of the propeptide of VWF has yet to be
fully defined, it has been demonstrated to be critical for
multimerization and intracellular storage of the mature VWF protein.8-10 The 741-amino acid (aa) propeptide
represents 26.3% of the primary translation pro-VWF product and
consists of 2 homologous D domains that are cysteine-rich, with 32 cysteines in each D domain. The multimerization of pro-VWF
dimers involves intermolecular disulfide bridges created between
cysteine residues in the D3 domains of adjacent VWF
molecules.5,11 The propeptides of several hormones and
enzymes have been demonstrated to assist in the correct folding of the
mature peptide and have been termed "intramolecular
chaperones."12,13 The VWFpp may function as an
intramolecular chaperone to assist in VWF protein folding during multimerization and to promote vesicular segregation of VWF into storage granules.
This study represents a functional characterization of a naturally
occurring mutation in the VWFpp. Although the patient in our study has
mild VWD, the VWF multimer pattern has an unusual phenotype with a
markedly increased dimer band among a relatively normal distribution of
the remaining VWF multimers. In this report, we describe how a
congenital defect located in the VWFpp results in a complete loss of
VWF multimerization but maintenance of normal vesicular storage of VWF.
The natural intramolecular chaperone function of the VWFpp has been
altered by this defect. Heterozygosity in this patient presented a
unique opportunity to study a VWF dimer mutant in vitro and determine
the extent to which the VWFpp functions intracellularly during
VWF multimer assembly in the secretory pathway.
Isolation of total cellular RNA and genomic DNA
Reverse transcription-PCR and cDNA sequencing
Tyr87Ser mutant plasmid construction The VWF expression vector pvW198 (a gift of Dennis Lynch, Dana Farber Cancer Center, Boston, MA) was digested with restriction enzymes XhoI and KpnI (Promega), and the resulting 525-bp fragment was cloned into pGEM7-Zf+ for use as mutagenic PCR template (Promega). Two separate first-round PCRs were performed with the use of the M13 forward universal primer (M13F) with aVWF271-249-mutant nucleotide (aVWF271-249-m) (ATTCCCCAAGAgACACGGAGAGG) producing a 590-bp product, and svWF249-271-m (CCTCTCCGTGTcTCTTGGGGAAT) with M13 reverse universal primer (M13R) producing a 174-bp product. A second round of PCR was performed on 2 µL of the first-round products and amplified with M13F and M13R. The resulting PCR fragment was then cloned into the XhoI/KpnI site of pG3vW-1 (an intermediate cloning vector constructed by cloning the 3302-bp SalI-KpnI fragment of pvW198 into the SalI-KpnI site of pGEM3-Zf+ [Promega]). Finally, the vector expressing the Tyr87Ser-VWF defect (pvW198-Br) was constructed by a 3-fragment ligation with the use of the mutant 3302-bp SalI/KpnI fragment of pG3vW-1, and the 2415-bp KpnI/BamHI and the 7083-bp BamHI/SalI fragments of pvW198. Introduction of the patient's mutation into normal VWF sequence was verified by sequencing. A vector expressing only the propeptide containing the Tyr87Ser mutation was constructed by ligating a fragment containing the mutation into the previously described8 VWFpp expression vector.Cell culture Established cell culture lines were used in the course of this study: monkey kidney cells (COS-7; ATCC, Rockville, MD); mouse pituitary tumor cells (AtT-20/D16v-F2; ATCC); and human embryonic kidney cells (HEK 293T; provided by D. Ginsburg, University of Michigan, Ann Arbor, MI). AtT-20 cells are an adrenocorticotropic hormone (ACTH)-synthesizing model storage and secretory cell line16 that does not synthesize VWF, but will store VWF when transfected with VWF cDNA.8,10 COS-7 and HEK-293T cells are nonstorage cell lines used for high expression of VWF without VWF storage. All cell lines were cultured at 37°C in a 5% CO2 humidified incubator in either complete AtT-20 or HEK293T medium as previously described,8 or complete COS medium (RPMI 1640 [Life Technologies, Rockville, MD]; 10% fetal bovine serum [FBS]; and 2 mM L-glutamine].Transient and stable expression of VWF VWF expression vectors were transiently transfected into COS-7 cells and HEK-293T cells with the use of lipofectin (Life Technologies) and into AtT-20 cells with the use of lipofectamine (Life Technologies). Optimized transfection conditions were previously determined.3,17 Briefly, 24 hours prior to transfections, cultured cells were plated at 5 × 105 cells (COS-7) in 60-mm culture dishes or at 4 × 106 cells (AtT-20) in 100-mm dishes. Cells were incubated in OPTI-MEM I-reduced serum medium (Life Technologies) diluted with either 15 µg DNA plus 40 µg lipofectin or 8 µg DNA plus 192 µg lipofectamine for 5 hours at 37°C for the COS-7 and AtT-20 cell transfections, respectively. The DNA/lipid complexes were removed and replaced with complete media (with 10% FBS), and the plasmids were transiently expressed for 72 hours. Conditioned media were harvested from the cells, centrifuged to remove cellular debris, and analyzed by solid-phase capture enzyme-linked immunosorbent assays (ELISAs)18 and functional fluid-phase assays.18,19 The transfected cells were then lysed or fixed for immunofluorescent staining (see "Immunofluorescence staining"). AtT-20 cells were used to establish stable transfections of wild-type VWF (WT-VWF) (pvW198.1) or Tyr87Ser-VWF mutant (pvW198-Br) with the use of the selection agent G418 (Sigma, St Louis, MO) at 0.3 mg/mL. After several weeks of selection, positive colonies were selected by analysis of the secreted VWF in the conditioned media by VWF antigen-capture ELISA.Antibodies used Antibodies used in this study include AP-1, AVW-1, AVW-3, AVW-5, AVW-17, MBC 33.5, and polyclonal anti-VWF antibodies. The Hybridoma Core Laboratories at the Blood Center of Southeastern Wisconsin (Milwaukee) produced all above antibodies. AP-1 is a monoclonal antibody (mAb) against GPIb that inhibits the platelet GPIb
binding of VWF. The monoclonal antibodies AVW-1, AVW-3, AVW-5, and
AVW-17 recognize distinct epitopes in mature VWF. MBC 33.5 is an
anti-VWFpp mAb.
Multimer analysis Expressed VWF was immunoprecipitated from conditioned media with the use of mAb AVW-1 (anti-VWF) or MBC 33.5 (anti-VWFpp) covalently coupled to sepharose 4B agarose beads (Pharmacia Biotech, Piscataway, NJ), and eluted as previously described with the use of a buffer containing 8 M urea/6% sodium dodecyl sulfate (SDS)/13 mM Tris (tris(hydroxymethyl)aminomethane)/1 mM EDTA (ethylenediaminetetraacetic acid)/0.05% bromphenol blue (pH, 8.8).18 The eluted samples were electophoresed through 0.65% or 1.5% HGT(P) agarose (FMC Bioproducts, Rockland, ME) gels containing 1% SDS for 16 hours at 40 V. The protein was transblotted to nitrocellulose for 30 minutes at 35 V followed by 4 hours at 50 V. Membranes were blocked with 5% nonfat dry milk, incubated overnight with mAbs AVW-5 and AVW-17, and then incubated for 2 hours with horseradish peroxidase (HRP)-conjugated goat antimouse immunoglobulin G (IgG) (Pierce, Rockford, IL). Membranes were treated with electrogenerated chemiluminescent (ECL) substrate (Amersham Life Science, Arlington Heights, IL), and bands were detected by exposure to autoradiography film.Platelet-binding assays Binding of expressed VWF to platelets was determined by means of a modification of the platelet-binding assay previously described by our laboratory.19 In these assays, conditioned media samples from transiently transfected cells were diluted to equal amounts of VWF (determined by ELISA) and mixed with 125I-labeled AVW-1 (anti-VWF mAb). After 60 minutes, formalin-fixed human platelets were added to this mixture in the presence or absence of either ristocetin (1.2 mg/mL) or botrocetin (1.0 µg/mL) under nonstirring conditions. After 30 minutes, reactions were centrifuged at 10 000g for 10 minutes. Both platelet pellets and supernatants were counted to quantitate the amount of VWF bound to the platelets as determined by measuring the 125I-AVW-1. All data were averaged from 6 independent assays of separate transient transfections and normalized to WT-VWF, which has been established as 100% binding. Controls included media from nontransfected cells and diluted normal pool plasma.Collagen binding Binding of expressed VWF to collagen was determined in a microtiter plate assay. Immulon I 96-well plates (Dynatech, Chantilly, VA) were coated with 300 ng per well of collagen Type III from human placenta (Sigma). Fixed amounts of expressed recombinant VWF (rVWF) (100 ng/mL) were added to the collagen plate and incubated for 60 minutes. Samples were incubated with polyclonal anti-VWF antiserum for 30 minutes and then incubated with AP-conjugated goat antirabbit IgG (Pierce) for 30 minutes. Color was developed with ImmunoSelect substrate (Life Technologies) and read at 492 nm in the ThermoMax microplate reader (Molecular Devices, Menlo Park, CA). The relative amount of VWF bound (VWF:CB) was calculated by means of SOFTmax, version 2.34 (Molecular Devices), on the basis of a standard curve generated by plating serially diluted pooled normal human plasma.FVIII binding Binding of FVIII to VWF was measured in a microtiter plate assay essentially as described by Nishino et al20 and modified by Kroner et al.17,18 Samples were diluted to a final VWF concentration of 10 mU/mL. Equal volumes were added to an AVW-1-coated microtiter plate (Immulon I) and incubated for 2 hours. Plates were washed and incubated for 1 hour at 37°C with 50 µL recombinant human FVIII (Baxter Healthcare, Glendale, CA) ranging in concentration from 0 to 4 U/mL. Plates were washed, and the VWF-bound FVIII was determined by chromogenic assay by means of the Chromogenix Coatest FVIII:C/4 kit (diaPharma, West Chester, OH). Plates were incubated at 37°C for the enzymatic reactions, and the resulting chromogenic substrate conversion was read at 405 nm in the ThermoMax reader. The amount of FVIII bound was calculated by means of SOFTmax software, on the basis of a standard curve generated by the addition of serially diluted r-hFVIII to microtiter plates wells prior to the chromogenic FVIII assay.Immunofluorescence staining Cultured cells transfected with VWF plasmids were analyzed for the subcellular localization of VWF with immunofluorescent antibody labeling of the expressed antigens and confocal laser scanning microscopy, as previously described.3,21 Transfected AtT-20 cells were grown on 35-mm culture plates (Fisher Scientific, Itasca, IL) in Dulbecco modified Eagle medium/G418 media for 72 hours. Negative controls (nontransfected and mock-transfected cells) were processed in parallel with each immunofluorescence labeling experiment. The cells were processed and immunofluorescently labeled by the sequential antibody staining method.10,22 Purified anti-VWF monoclonal and polyclonal antibodies, and anti-VWFpp monoclonal antibodies, were used as primary antibodies. Fluorescein isothiocyanate (FITC)- and Texas Red (TXR)-conjugated donkey IgG (H + L) (F(ab')2 fragments) (Jackson ImmunoLabs, West Grove, PA) were the secondary antibodies (diluted at 1:200 and 1:1000, respectively).Submarine gel analysis To examine the formation of homodimers and heterodimers of VWF, 2 types of VWF were expressed. Wild-type VWF was coexpressed with hereditary persistence of pro-VWF (HPP-VWF) that contains a disrupted furin-cleavage site. The HPP-VWF mutation was identified in a patient and results in an alternative splice ( bp2269-2270 and
bp2282-2288) that changes the amino acid sequence from
756Pro-Leu-Ser-His-Arg-Ser-Lys-Arg-Ser-Leu-Ser
to 756Pro-Val-Ser-Ser-Glu-Ser-Leu-Ser
(underlined sequence is mature VWF sequence).23 The
HPP-VWF expresses a pro-VWF that is 741 amino acids larger than
wild-type VWF, contains uncleaved propeptide, multimerizes, and is
stored in granules in AtT-20 cells.23 This HPP-VWF was
used to create a larger protein that could be distinguished from
wild-type VWF by SDS-agarose electrophoresis. The 2 VWF constructs were
expressed independently and coexpressed in HEK293T cells with the use
of the transfection conditions as described above. A DNA ratio of 40:1
(HPP-VWF to WT-VWF) was used and had been optimized to produce similar
concentrations of the 2 types of expressed VWF. Culture supernatants
were harvested and quantitated by ELISA. Samples were analyzed on a 3%
MetaPhor Agarose gel (FMC BioProducts) dissolved in 90 mM
Tris, 90 mM boric acid, pH 8.5; and run in the same buffer in the
presence of 0.1% SDS by means of a BioRad Submarine Gel System at 7.5 mA (40 V) for 16 hours at 4°C. Western blotting was performed as
described above.
Identification and expression of mutant VWF In the process of studying a family with clinical symptoms of type 1 VWD, we discovered that the mother and the daughter had a previously unreported multimer pattern. A heavy predominance of VWF dimers was observed in both plasmas (Figure 1, lanes 1, 2), equaling approximately 50% of the total VWF antigen, while the remainder of the VWF appeared to multimerize normally. A single missense mutation (260A>C) was identified in exon 4 (D1 domain), converting Tyr87 to a serine (Tyr87Ser) (Figure 2). When a VWF expression vector containing this mutation was transfected into COS-7 cells, the expressed VWF consisted predominantly of dimers, with a nearly complete loss of multimerization beyond the dimer band (Figure 3, lanes 2, 3).
Effect of dimeric VWF on platelet binding To determine whether the VWFpp mutation had an effect on the platelet-binding function of VWF, we analyzed the binding capability of expressed VWF in platelet-binding assays performed with ristocetin and botrocetin as agonists (Table 1). The antibiotic ristocetin was used to induce the interaction between VWF and the platelet GPIb receptor.6 Botrocetin binds
directly to the A1 loop of VWF, which contains the GPIb-binding domain,
and induces the binding of VWF to platelet GPIb.1 The
expressed WT-VWF bound as expected to platelets when induced by either
ristocetin or botrocetin, similarly to pooled normal human plasma
(NP) controls run for each assay (data not shown). While the
Tyr87Ser mutant rVWF showed normal botrocetin-induced platelet binding
(97.2% of control WT), there was a marked loss of ristocetin-induced
platelet binding (16.8% of control WT).
Further functional characterization of the dimeric VWF species We questioned whether the other functions of VWF might be similarly affected. We explored the potential effects on the critical VWF functions of collagen and FVIII binding by the dimeric VWF species. Since VWF interactions with subendothelial matrix proteins such as collagen are necessary to promote platelet adhesion and wound repair, we analyzed the ability of the recombinant VWF dimers to bind collagen. Compared with the VWF expressed by WT-VWF-transfected cells, the rVWF dimers expressed by Tyr87Ser-VWF-transfected cells displayed only 23% of the collagen-binding potential (Table 1).In a solid-phase assay for VWF-to-FVIIIB activity, mAb-captured expressed rVWF was incubated with rFVIII in varying amounts (see "Materials and methods"). Table 1 compares the binding of FVIII results with rVWF samples from transient transfections of WT, Arg854Gln, Tyr87Ser, and mock plasmids. The Arg854Gln is a type 2N mutant construct shown to bind only 20% to 25% of rFVIII as compared with wild-type VWF. Binding of FVIII to the dimeric (Tyr87Ser mutant) rVWF species was detected, albeit at reduced levels (Tyr87Ser at 36.6% of WT), similar to that seen with the Arg854Gln VWF (26.1% of WT). Additionally, when an assay was performed with the use of plasma from this family in place of the cultured media samples (data not shown), the ratio of FVIII bound to VWF captured was between 53% and 62% (normal plasma controls were 91%). In this assay, a heterozygote 2N VWD control displayed a binding ratio of 53%, indicating that the patient's plasma possesses a degree of FVIII binding similar to that of the control 2N VWF. Intracellular storage of Tyr87Ser-VWF Since multimerization occurs prior to VWF regulated storage,8,22 we next addressed whether this VWFpp mutation would affect VWF intracellular storage. When expressed in AtT-20 cells, the Tyr87Ser dimeric VWF and WT-VWF were secreted at similar levels (303 ± 18 versus 264 ± 27 ng VWF per 1 × 106 cells, respectively). To determine whether a dimeric VWF species could be stored in secretory granules, AtT-20 cells expressing mutant and wild-type VWF were stained with anti-VWF mAbs to assess intracellular localization of VWF. The punctate granular pattern detected by indirect immunofluorescent microscopy of cells expressing Tyr87Ser-VWF (Figure 4B) appears as small and medium-sized granules similar to those observed in WT-VWF expressing AtT-20 cells (Figure 4A). Additional experiments focused on the capability of the mutant propeptide to direct noncontiguous VWF protein to storage. When the Tyr87Ser-VWFpp and mature VWF (pro)8 plasmids
were cotransfected in AtT-20 cells as 2 separate gene products
(in trans), both the mutant propeptide (Figure
5, top panel) and VWF (Figure 5, center panel) were stored colocalized in granules as shown in the lower panel
of Figure 5.
Formation of VWF dimers Patient plasma exhibited what appeared to be dimers from the abnormal allele and normal multimers from the normal allele as displayed in Figure 1. Recently, Bodo et al24 reported heterodimerization of a mutant (Cys1149Arg) VWF and normal subunits as the cause of intracellular retention and degradation resulting in a quantitative VWF deficiency. To investigate the origin of the patient multimer patterns, we examined whether the predominant protomeric species was a homodimer derived from message from the same allele. In addition to wild-type VWF, a second construct (HPP-VWF) expressing pro-VWF with a disrupted furin-cleavage site was used to create a larger protein that could be distinguished from wild type by SDS-agarose gel electrophoresis. This HPP-VWF protein has been shown to multimerize normally.23 The 2 VWF constructs were expressed independently and coexpressed in HEK293T cells. The resulting conditioned media were analyzed on submarine MetaPhor-agarose gels that better define dimeric VWF molecules (Figure 6). As shown in Figure 6, our results demonstrate that there was not significant formation of heterodimers (less than 10%, lane 1, middle band). Instead, the predominant species appears to be mainly homodimers (39% HPP-VWF, lane 1, upper band, and 52% WT-VWF, lane 1, lower band). These experiments were repeated with the use of a VWF deletion mutant (A3 domain deleted) with the HPP-VWF. Similar results were obtained: 8% heterodimer, 46% HPP-VWF homodimer, and 46%A3-VWF homodimer (data not shown).
Our laboratory has been investigating the role of the VWFpp in the processing of the mature VWF molecule. A key congenital mutation was discovered in the VWFpp resulting in an unusual multimerization pattern in which there is a marked increase of the protomeric species of VWF, C-terminal dimers. The multimeric pattern displayed in Figure 1 is different from those published for subtype IIC VWD,25 which also contain an overabundance of the dimeric species but with a selective loss of the high-molecular weight VWF multimers when studied with low-percentage agarose electrophoresis. The abnormality (Tyr87Ser) in this study is one that affects the later stages of VWF biosynthesis: the generation of VWF multimers. When this mutation (Tyr87Ser) was introduced into a VWF expression vector, the secreted VWF was nearly exclusively the dimeric subunit (Figure 3). Previous experiments indicated that multimerization is a process that is separate from dimerization.5,9,26 Our studies confirm these findings; the Tyr87Ser VWFpp defect directly affects the multimerization process of VWF. Furthermore, lack of multimerization did not preclude storage in AtT-20 cells (Figures 4 and 5), confirming that multimerization and granular storage are 2 independent processes.8 We theorize that the multimer pattern presented in Figure 1 is the result of multimers derived from separate alleles synthesizing wild-type (full-length multimers) and mutant VWF (dimer molecules) with little evidence for production of heterodimers. Recently, Bodo et al24 reported that a Cys1141Arg mutation in VWF had a dominant negative effect, causing endoplasmic reticulum retention of the normal subunit as a result of heterodimer formation with the mutant subunit. In this report, we did not find a random formation of heterodimer. In our study, we observed that less than 10% of the dimer population consisted of heterodimers (Figure 6). This result was obtained with the use of essentially wild-type VWF proteins or A3 domain-deleted VWF. We have found the propensity for dimer formation to be primarily homodimeric, indicating that assembly of dimers (C-terminal) may occur cotranslationally. The drive for homodimer formation could be the result of C-terminal interaction with the nearest neighboring VWF monomer, which most likely would be a monomer being produced by the same polysome and therefore the same mRNA molecule. Although the mutation affects the propeptide, the inhibitory effect of this defect manifests itself in a dramatic loss of several critical functions for the processed VWF protein. While the ability of the dimeric rVWF to participate in botrocetin-induced platelet binding was unaffected, the dimeric rVWF displayed diminished ristocetin-induced platelet binding, collagen binding, and FVIII binding (Table 1). The decrease in platelet binding to these dimers in the presence of ristocetin is not surprising, since it is known that high-molecular weight multimers have a greater predilection for platelets in the presence of ristocetin.6 In contrast, botrocetin is not affected by the multimeric size of VWF.6 Even though the binding sites for collagen in the A1 and A3 domains are not mutated, there was a marked decrease in rVWF dimer binding to type III collagen (Table 1). This could be attributed to the loss of HMW multimers since it has been shown that the highest MW multimers bind collagen with the greatest avidity.1,6 The dimeric rVWF also binds FVIII, but at reduced levels, similar to type 2N VWD controls. This suggests a dependency of FVIII binding on VWF multimer size, and rVWF binding of FVIII may depend on the degree of cooperation between neighboring FVIII-binding sites in more fully multimerized VWF molecules. Defects and deletions in the propeptide of VWF have demonstrated
the obligatory nature of VWFpp in the multimerization process. Experiments involving deletion of parts of VWFpp ( Propeptides of peptide hormones have been reported to act upon their
mature subunits as intramolecular chaperones, including subtilisin,
preprosomatostatin, lactase-phlorizin hydrolase, and prouroguanylin.32-35 The uncleaved, contiguous propeptide
functions at only one point in the folding pathway: assisting in
protein folding and stabilization prior to protein
maturation.32 These chaperones remain attached to the
mature sequence until the maturation process is complete, and then are
proteolytically removed by autoprocessing or another
endopeptidase.32 Analogous to other intramolecular chaperones, the lengthy propeptide (741 aa) of VWF appears to stabilize
the intramolecular disulfide interactions between cysteines within
individual D1, D2, and D3 domains. It is our hypothesis that the
propeptide of VWF functions during the maturation process as an
intramolecular chaperone. In our model (Figure
7), the propeptide serves as a molecular
chaperone during the final stages of protein folding, aligning the
dimeric pro-VWF subunits in the proper spacial arrangement necessary to
create disulfide bridges between the free sulfhydryls in N-termini (D3
domain) of adjacent pro-VWF molecules.
The tertiary and quaternary structures have yet to be deciphered for
VWFpp. Hence, it is not known how the Tyr87Ser mutation would disrupt
the structure or function of the VWFpp. In order for a defect to
inhibit the multimerization of VWF, it must disrupt the alignment of
the VWFpp and the mature VWF protein. We have discovered that our novel
mutation is situated in a highly conserved region of the VWFpp.
Alignment of the human VWFpp with the VWFpp's of 4 divergent mammals
(canine,8 porcine [unpublished, accession no. AY004876],
bovine,36 and murine [unpublished sequence obtained in
our laboratory]) shows an expanse of 12 aa's that are perfectly
conserved around the mutation (Figure 8).
This defect must disrupt the conformation of VWFpp in such a way
that its ability to function as an intramolecular chaperone is
impaired.
A second potential function ascribed to the VWFpp is to direct VWF into
vesicular storage via an intrinsic TGN-sorting signal.8,26 When the dimer-generating VWF mutant was expressed in AtT-20 cells, granular storage of transfected VWF was observed (Figure 4).
Furthermore, as the double transfection (in trans) with
Tyr87Ser-VWFpp and The correct folding of VWF into C-terminal dimers does occur without the presence of an intact VWFpp. However, if the VWFpp is defective, the final stages of VWF biosynthesis (N-terminal multimerization) are aberrant with no multimerization observed. It is evident that there are multiple domains or motifs present in the propeptide of VWF that together in the correct tertiary configuration confer this function. The entire propolypeptide appears to function in this chaperone capacity; thereby, missense mutations (eg, Tyr87Ser) abolish this vital VWF biosynthesis function. The propeptide functions as an obligatory intramolecular chaperone necessary for the correct alignment of the C-terminal dimers into the tail-to-tail position during VWF N-terminal multimerization.
Submitted March 13, 2002; accepted April 17, 2002.
Prepublished online as Blood First Edition Paper, May 13, 2002; DOI 10.1182/blood-2002-03-0789.
Supported by grants from the National Hemophilia Foundation
J.B.R. and S.L.H. contributed equally to this work.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Robert R. Montgomery, Department of Pediatrics, The Medical College of Wisconsin, 8701 W Watertown Plank Rd, Milwaukee, WI 53226; e-mail: bob{at}bcsew.edu.
1. Wagner DD. Cell biology of von Willebrand factor [review]. Annu Rev Cell Biol. 1990;6:217-246[CrossRef][Medline] [Order article via Infotrieve]. 2. Verweij CL, Diergaarde PJ, Hart M, Pannekoek H. Full-length von Willebrand factor (vWF) cDNA encodes a highly repetitive protein considerably larger than the mature vWF subunit [published erratum appears in EMBO J 1986;5:3074]. EMBO J. 1986;5:1839-1847[Medline] [Order article via Infotrieve]. 3. Rosenberg JB, Foster PA, Kaufman RJ, et al. Intracellular trafficking of factor VIII to von Willebrand factor storage granules. J Clin Invest. 1998;101:613-624[Medline] [Order article via Infotrieve].
4.
Wagner DD, Olmsted JB, Marder VJ.
Immunolocalization of von Willebrand protein in Weibel-Palade bodies of human endothelial cells.
J Cell Biol.
1982;95:355-360 5. Voorberg J, Fontijn R, van Mourik JA, Pannekoek H. Domains involved in multimer assembly of von willebrand factor (vWF): multimerization is independent of dimerization. EMBO J. 1990;9:797-803[Medline] [Order article via Infotrieve]. 6. Montgomery RR, Coller BS. Von Willebrand disease. In: Colman RW,Hirsh J,Marder VJ,Salzman EW, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Philadelphia, PA: JB Lippincott; 1994:134-168. 7. Sadler JE, Mannucci PM, Berntorp E, et al. Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost. 2000;84:160-174[Medline] [Order article via Infotrieve].
8.
Haberichter SL, Fahs SA, Montgomery RR.
von Willebrand factor storage and multimerization: 2 independent intracellular processes.
Blood.
2000;96:1808-1815 9. Journet AM, Saffaripour S, Wagner DD. Requirement for both D domains of the propolypeptide in von Willebrand factor multimerization and storage. Thromb Haemost. 1993;70:1053-1057[Medline] [Order article via Infotrieve]. 10. Wagner DD, Saffaripour S, Bonfanti R, et al. Induction of specific storage organelles by von Willebrand factor propolypeptide. Cell. 1991;64:403-413[CrossRef][Medline] [Order article via Infotrieve]. 11. Marti T, Rosselet SJ, Titani K, Walsh KA. Identification of disulfide-bridged substructures within human von Willebrand factor. Biochemistry. 1987;26:8099-8109[CrossRef][Medline] [Order article via Infotrieve]. 12. Inouye M. Intramolecular chaperone: the role of the pro-peptide in protein folding. Enzyme. 1991;45:314-321[Medline] [Order article via Infotrieve]. 13. Shinde U, Inouye M. Intramolecular chaperones: polypeptide extensions that modulate protein folding. Semin Cell Dev Biol. 2000;11:35-44[CrossRef][Medline] [Order article via Infotrieve].
14.
Kroner PA, Kluessendorf ML, Scott JP, Montgomery RR.
Expressed full-length von Willebrand factor containing missense mutations linked to type IIB von Willebrand disease shows enhanced binding to platelets.
Blood.
1992;79:2048-2055 15. Newman PJ, Gorski J, White GC, Gidwitz S, Cretney CJ, Aster RH. Enzymatic amplification of platelet-specific messenger RNA using the polymerase chain reaction. J Clin Invest. 1988;82:739-743[Medline] [Order article via Infotrieve]. 16. Moore HP, Walker MD, Lee F, Kelly RB. Expressing a human proinsulin cDNA in a mouse ACTH-secreting cell: intracellular storage, proteolytic processing, and secretion on stimulation. Cell. 1983;35:531-538[CrossRef][Medline] [Order article via Infotrieve].
17.
Kroner PA, Friedman KD, Fahs SA, Scott JP, Montgomery RR.
Abnormal binding of factor VIII is linked with the substitution of glutamine for arginine 91 in von Willebrand factor in a variant form of von Willebrand disease.
J Biol Chem.
1991;266:19146-19149
18.
Kroner PA, Foster PA, Fahs SA, Montgomery RR.
The defective interaction between von Willebrand factor and factor VIII in a patient with type 1 von Willebrand disease is caused by substitution of Arg19 and His54 in mature von Willebrand factor.
Blood.
1996;87:1013-1021 19. Scott JP, Montgomery RR. The rapid differentiation of type IIb von Willebrand's disease from platelet-type (pseudo-) von Willebrand's disease by the "neutral" monoclonal antibody binding assay [Comment appears in Am J Clin Pathol. 1991;96:681-683]. Am J Clin Pathol. 1991;96:723-728[Medline] [Order article via Infotrieve].
20.
Nishino M, Girma JP, Rothschild C, Fressinaud E, Meyer D.
New variant of von Willebrand disease with defective binding to factor VIII.
Blood.
1989;74:1591-1599
21.
Rosenberg JB, Greengard JS, Montgomery RR.
Genetic induction of a releasable pool of factor VIII in human endothelial cells.
Arterioscler Thromb Vasc Biol.
2000;20:2689-2695
22.
Vischer UM, Wagner DD.
von Willebrand factor proteolytic processing and multimerization precede the formation of Weibel-Palade bodies.
Blood.
1994;83:3536-3544 23. Kroner PA, Foster PA, Fahs SA, Montgomery RR. Persistence of pro-vWf, an inherited cause of reduced factor VIII binding, and its comparison with other factor VIII binding vWf mutants [abstract]. Thromb Haemost. 1993;69:1212.
24.
Bodo I, Katsumi A, Tuley EA, Eikenboom JC, Dong Z, Sadler JE.
Type 1 von Willebrand disease mutation Cys1149Arg causes intracellular retention and degradation of heterodimers: a possible general mechanism for dominant mutations of oligomeric proteins.
Blood.
2001;98:2973-2979
25.
Gaucher C, Dieval J, Mazurier C.
Characterization of von Willebrand factor gene defects in two unrelated patients with type IIC von Willebrand disease.
Blood.
1994;84:1024-1030
26.
Mayadas TN, Wagner DD.
Vicinal cysteines in the prosequence play a role in von Willebrand factor multimer assembly.
Proc Natl Acad Sci U S A.
1992;89:3531-3535 27. Wise RJ, Pittman DD, Handin RI, Kaufman RJ, Orkin SH. The propeptide of von Willebrand factor independently mediates the assembly of von Willebrand multimers. Cell. 1988;52:229-236[CrossRef][Medline] [Order article via Infotrieve].
28.
Mayadas TN, Wagner DD.
In vitro multimerization of von Willebrand factor is triggered by low pH: importance of the propolypeptide and free sulfhydryls.
J Biol Chem.
1989;264:13497-13503
29.
Allen S, Abuzenadah AM, Hinks J, et al.
A novel von Willebrand disease-causing mutation (Arg273Trp) in the von Willebrand factor propeptide that results in defective multimerization and secretion.
Blood.
2000;96:560-568 30. Gaucher C, Uno H, Yamazaki T, Mashiba H, Mazurier C. A new candidate mutation (N528S) within the von Willebrand factor propeptide identified in a Japanese patient with phenotype IIC of von Willebrand disease. Eur J Haematol. 1998;61:145-148[Medline] [Order article via Infotrieve]. 31. Schneppenheim R, Thomas KB, Krey S, et al. Identification of a candidate missense mutation in a family with von Willebrand disease type IIC. Hum Genet. 1995;95:681-686[CrossRef][Medline] [Order article via Infotrieve].
32.
Shinde U, Li Y, Chatterjee S, Inouye M.
Folding pathway mediated by an intramolecular chaperone.
Proc Natl Acad Sci U S A.
1993;90:6924-6928
33.
Stoller TJ, Shields D.
The propeptide of preprosomatostatin mediates intracellular transport and secretion of alpha-globin from mammalian cells.
J Cell Biol.
1989;108:1647-1655
34.
Naim HY, Jacob R, Naim H, Sambrook JF, Gething MJ.
The pro region of human intestinal lactase-phlorizin hydrolase [published erratum appears in J Biol Chem. 1994;270:986].
J Biol Chem.
1994;269:26933-26943
35.
Hidaka Y, Shimono C, Ohno M, et al.
Dual function of the propeptide of prouroguanylin in the folding of the mature peptide: disulfide-coupled folding and dimerization.
J Biol Chem.
2000;275:25155-25162 36. Janel N, Schwachtgen JL, Bakhshi MR, Barek L, Meyer D, Kerbiriou-Nabias D. Comparison of the 5'-flanking sequences of the human and bovine von Willebrand factor-encoding genes reveals alternation of highly homologous domains with species-specific Alu-type repeats. Gene. 1995;167:291-295[CrossRef][Medline] [Order article via Infotrieve].
37.
Hop C, Guilliatt A, Daly M, et al.
Assembly of multimeric von Willebrand factor directs sorting of P-selectin.
Arterioscler Thromb Vasc Biol.
2000;20:1763-1768 38. Voorberg J, Fontijn R, Calafat J, Janssen H, van Mourik JA, Pannekoek H. Biogenesis of von Willebrand factor-containing organelles in heterologous transfected CV-1 cells. EMBO J. 1993;12:749-758[Medline] [Order article via Infotrieve].
© 2002 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  D. J. Metcalf, T. D. Nightingale, H. L. Zenner, W. W. Lui-Roberts, and D. F. Cutler Formation and function of Weibel-Palade bodies J. Cell Sci., January 1, 2008; 121(1): 19 - 27. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. L. Haberichter, E. P. Merricks, S. A. Fahs, P. A. Christopherson, T. C. Nichols, and R. R. Montgomery Re-establishment of VWF-dependent Weibel-Palade bodies in VWD endothelial cells Blood, January 1, 2005; 105(1): 145 - 152. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Michaux, L. J. Hewlett, S. L. Messenger, A. C. Goodeve, I. R. Peake, M. E. Daly, and D. F. Cutler Analysis of intracellular storage and regulated secretion of 3 von Willebrand disease-causing variants of von Willebrand factor Blood, October 1, 2003; 102(7): 2452 - 2458. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. L. Haberichter, P. Jacobi, and R. R. Montgomery Critical independent regions in the VWF propeptide and mature VWF that enable normal VWF storage Blood, February 15, 2003; 101(4): 1384 - 1391. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2002 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
S
